Janssen Touts Positive Mid-Late Stage Data From Two Ulcerative Colitis Trials

Janssen Pharmaceutical, a Johnson & Johnson company, announced data on Monday from two Ulcerative colitis (UC) trials.

This included data from the Stelara Phase III UNIFI trial and an ongoing analysis from the Phase IIa VEGA trial of guselkumab and golimumab, both for the treatment of Ulcerative colitis (UC).